CJC-1295 DAC vs Mecasermin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
CJC-1295 DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), built from a modified GRF(1-29) sequence with four amino acid swaps plus a Drug Affinity Complex (DAC) that lets it latch onto your own albumin after injection. That albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and IGF-1 up for over a week. It is not FDA approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide.
Also: Increlex, rhIGF-1
Mecasermin is recombinant human IGF-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. Sold as Increlex, it was FDA approved in 2005 for a narrow group: children with severe primary IGF-1 deficiency (mostly Laron syndrome) or a growth hormone gene deletion with antibodies against GH. In those kids it is the only thing that works, because GH cannot do its job. It is not a GH substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug.
Key Comparison Insights
- Mecasermin is FDA approved, while CJC-1295 DAC remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Mecasermin has stronger research evidence (FDA Approved) compared to CJC-1295 DAC (Human Trials).
Detailed Comparison
| Attribute | CJC-1295 DAC | Mecasermin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHRH is the natural signal your hypothalamus sends to the pituitary to release growth hormone in pulses. CJC-1295 binds and activates the same GHRH receptor on the pituitary, prompting it to make and release more of its own growth hormone, which then raises IGF-1 from the liver. The four amino acid substitutions make it resist breakdown by the enzyme DPP-IV, and the DAC linker covalently bonds it to circulating albumin so it is not cleared quickly. Because it amplifies the body's own pulsatile signaling rather than injecting growth hormone directly, the effect is a sustained elevation rather than a single spike. | Normally, growth hormone binds receptors in the liver and other tissues and triggers IGF-1 production. IGF-1 then activates the type 1 IGF receptor on bone, cartilage and other cells, driving growth. In Laron syndrome the GH receptor is broken, so GH levels are high but IGF-1 stays low. Mecasermin skips the broken step and supplies IGF-1 directly. Because the IGF-1 receptor is a close relative of the insulin receptor, and because IGF-1 can also bind the insulin receptor at higher levels, it lowers blood sugar. That is why the label says to give it within about 20 minutes of a meal or snack. It is mostly carried by IGF binding protein 3 in blood, and its clearance depends on IGFBP-3 levels; the label reports a mean terminal half-life of about 5.8 hours in children with severe primary IGF-1 deficiency. |
| Common Dosing | Limited community data available See research protocols | 0.04-0.08 mg/kg twice daily to start Twice daily |
| Administration | Subcutaneous injection | Subcutaneous injection, rotating sites, within about 20 minutes before or after a meal or snack |
| Typical Duration | 8-12 weeks typical | Long-term, until growth plates close (closed epiphyses are a contraindication) |
| Best Time to Take | Before bed or morning (fasted) | Shortly before or after a meal or snack, twice daily |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core human evidence is a single early-phase study, Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, in healthy adults. A single subcutaneous dose raised GH roughly 2 to 10 fold and IGF-1 about 1.5 to 3 fold, with GH staying up for 6 days or more and IGF-1 elevated for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days. The estimated half-life was about 5.8 to 8.1 days and no serious adverse reactions were reported in that short trial. Beyond that, the data is mostly animal work, such as a study showing once-daily CJC-1295 normalized growth in GHRH knockout mice. Importantly, clinical development by the original sponsor (ConjuChem) was stopped, and a related long-acting analog program saw a Phase II lipodystrophy study halted after a participant death, although the attending physician attributed that death to pre-existing coronary disease rather than the drug. So the honest read is: short-term pharmacology in humans is documented, but there are no long-term safety or efficacy trials, no approval, and real questions about chronically elevating IGF-1. | The approval rests on five pooled studies (four open-label, one placebo-controlled) in 71 children with severe primary IGF-1 deficiency, 87% of whom had Laron syndrome. Height velocity rose from 2.8 cm per year before treatment to 8.0 cm per year in year 1, then settled around 4.5 to 5.8 cm per year in later years, still above baseline. Height scores improved but these children stayed very short (mean height SDS went from -6.7 to about -5.2 after 8 years), so it helps rather than normalizes. Hypoglycemia was reported in 42% of children at least once, and tonsillar hypertrophy in 15%. The label carries warnings for hypoglycemic seizures, anaphylaxis, intracranial hypertension, slipped capital femoral epiphysis (added July 2025), scoliosis progression, and postmarketing reports of malignant neoplasms; malignancy is a contraindication. Ownership changed recently: Eton Pharmaceuticals bought Increlex from Ipsen in December 2024 and in 2025 licensed rights outside the US to Esteve. Adult use, anti-aging use, and bodybuilding use are off-label and unsupported by trials. |
Frequently Asked Questions: CJC-1295 DAC vs Mecasermin
What is the difference between CJC-1295 DAC and Mecasermin?
CJC-1295 DAC is a growth hormone peptide that cjc-1295 dac is a synthetic, long-acting analog of growth hormone-releasing hormone (ghrh), built from a modified grf(1-29) sequence with four amino acid swaps plus a drug affinity complex (dac) that lets it latch onto your own albumin after injection. that albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and igf-1 up for over a week. it is not fda approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide. Mecasermin is a growth hormone peptide that mecasermin is recombinant human igf-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. sold as increlex, it was fda approved in 2005 for a narrow group: children with severe primary igf-1 deficiency (mostly laron syndrome) or a growth hormone gene deletion with antibodies against gh. in those kids it is the only thing that works, because gh cannot do its job. it is not a gh substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 DAC or Mecasermin?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 DAC is typically used for growth hormone purposes, while Mecasermin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 DAC and Mecasermin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 DAC and Mecasermin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.